Gennaro: Melky's calculated risk

From SABR President Vince Gennaro at Diamond Dollars on August 20, 2012:

How much did Melky Cabrera spend on his performance-enhancing drugs (PED)? I don’t mean the purchase price of the testosterone boost, but rather the impact on his next contract and future career earnings.

From a purely financial standpoint, (I’ll leave the moral issue of taking a banned substance to others) was Melky’s attempt at cheating the system an economically sound choice? The answer to both of these questions depends on the impact PEDs had on Melky, the ballplayer. The post-PED, 2012 Cabrera was performing at an extraordinary level. Having already taken home the All-Star Game MVP, his .346 batting average, .906 OPS and 4.5 WAR (FanGraphs), put him on pace to have a 6.7 WAR season. His individual stats, coupled with the success of the Giants and their dependency on him to ignite their otherwise listless offense made him a viable candidate for the NL MVP award.

We’ll stop short of calling his recent performance “elite”, but he certainly elevated himself into the top 10 position players in the NL, earning him the tag of “star.”

Read the full article here:

This page was last updated August 21, 2012 at 12:17 pm MST.

Individual Memberships start at just $45/year

Become A Member Today

When you join SABR you are making a statement of support for baseball history. You are joining a worldwide community of people who love to read about, talk about and write about baseball.